BioMarin (BMRN) CEO reports tax-withholding share disposition

Rhea-AI Filing Summary

BioMarin Pharmaceutical Chief Executive Officer Alexander Hardy reported a routine share disposition related to taxes. On March 17, 2026, 4,252 shares of common stock were withheld at $56.05 per share to cover tax obligations. After this transaction, he directly held 214,635 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hardy Alexander

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		F		4,252	D	$56.05	214,635	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BioMarin (BMRN) report for CEO Alexander Hardy?

BioMarin reported that CEO Alexander Hardy had 4,252 shares of common stock withheld on March 17, 2026 for tax obligations. The shares were valued at $56.05 each and reflect a tax-withholding disposition, not an open-market trade.

Was the BioMarin (BMRN) CEO’s Form 4 transaction a stock sale?

The transaction was not an open-market sale. It was coded “F,” meaning 4,252 shares were disposed of to satisfy taxes. This type of tax-withholding disposition typically accompanies equity compensation events rather than discretionary buying or selling in the market.

How many BioMarin (BMRN) shares were involved in the CEO’s tax withholding?

The filing shows 4,252 shares of BioMarin common stock were withheld at $56.05 per share. This disposal was reported as a tax-withholding transaction, indicating shares were used to cover tax liabilities tied to equity compensation.

How many BioMarin (BMRN) shares does CEO Alexander Hardy hold after this Form 4?

After the reported tax-withholding transaction, Alexander Hardy directly held 214,635 shares of BioMarin common stock. This figure reflects his remaining direct ownership following the 4,252-share disposition used to satisfy tax obligations on March 17, 2026.

What does transaction code “F” mean in the BioMarin (BMRN) CEO’s Form 4?

Code “F” indicates payment of exercise price or tax liability by delivering securities. In this case, 4,252 shares were disposed of at $56.05 per share to cover tax obligations, rather than representing a voluntary market purchase or sale by the CEO.